How does a double homozygous MTHFR mutation (e.g., homozygous C677T and A1298C) affect sex hormone levels?

MTHFR Double Homozygous Mutations and Sex Hormones

There is no established clinical relationship between double homozygous MTHFR mutations (C677T and A1298C) and sex hormone dysfunction that warrants routine testing or treatment. The most authoritative guideline explicitly states that MTHFR variant testing should not be ordered as part of routine evaluation for reproductive or endocrine disorders 1.

Guideline-Based Position

The American College of Medical Genetics and Genomics (ACMG) 2025 guidelines clearly state that MTHFR analysis should not be ordered for reproductive carrier screening or as part of routine evaluation for thrombophilia or reproductive complications 1. This position is supported by the American College of Obstetricians and Gynecologists (ACOG) and British hematology societies 1.

The rationale: While MTHFR variants reduce enzyme activity and can lead to mild hyperhomocysteinemia, recent meta-analyses show no significant association between MTHFR variants and adverse reproductive outcomes, questioning the clinical utility of such testing 1.

Research Evidence on Sex Hormones

Despite the guideline recommendations against routine testing, research studies have identified some associations with sex hormones, though these findings lack clinical actionability:

In Women:

Anti-Müllerian Hormone (AMH):

• The C677T TT genotype is associated with higher serum AMH levels (4.5 ± 3.2 ng/mL vs lower in other genotypes) 2
• Paradoxically, despite higher AMH, the TT genotype correlates with fewer oocytes retrieved during IVF stimulation 3
• The A1298C CC genotype shows a trend toward higher AMH levels (4.15 ± 1.67 ng/mL) but with decreased oocyte numbers 4

Androgenicity:

• The C677T polymorphism (Ala222Val) is associated with increased testosterone, free androgen index (FAI), and free estrogen index (FEI) in postmenopausal women 5
• This same variant correlates with decreased SHBG and increased central adiposity (higher BMI and waist-to-hip ratio) 5

In Men:

Luteinizing Hormone:

• Men with the C677T CC genotype (wild-type) have significantly higher plasma LH levels compared to CT or TT carriers 6
• No direct relationship was found between the C677T polymorphism and erectile dysfunction itself 6

Clinical Implications

What This Means in Practice:

1. Do not order MTHFR testing for patients presenting with:

   • Infertility concerns
   • Menstrual irregularities
   • Suspected hormonal imbalances
   • Erectile dysfunction
   • Recurrent pregnancy loss

2. If MTHFR mutations are incidentally discovered (through genetic testing for other indications):

   • Do not attribute reproductive or hormonal symptoms to these variants
   • Focus on standard endocrine evaluation with FSH, LH, estradiol, testosterone, and SHBG as clinically indicated 7
   • Manage any identified hormonal abnormalities according to standard endocrine guidelines 8, 9

3. The only MTHFR-related intervention with evidence is treating elevated homocysteine levels (>15-30 μmol/L) with:

   • Oral 5-methyltetrahydrofolate (5-MTHF) for C677T TT genotype specifically, as this bypasses the defective MTHFR enzyme 10
   • Standard folate (400 μg/day) achieves 25-30% homocysteine reduction in general population 10

Common Pitfalls to Avoid:

• Do not prescribe high-dose folate or B-vitamins based solely on MTHFR genotype without documented hyperhomocysteinemia
• Do not attribute infertility or hormonal dysfunction to MTHFR mutations—pursue standard diagnostic workup
• Do not use MTHFR status to guide contraceptive choices; the thrombophilia risk is not clinically significant for these variants 1

The Homocysteine Connection

The theoretical mechanism linking MTHFR to sex hormones involves homocysteine metabolism affecting vascular function and potentially ovarian/testicular blood flow. However:

• MTHFR variants cause only mild hyperhomocysteinemia in most cases 10
• The vascular effects are modest and do not translate to clinically meaningful reproductive outcomes 1
• Moderate hyperhomocysteinemia (15-30 μmol/L) should be treated by addressing the underlying cause (diet, B-vitamin deficiency, renal function, thyroid function) rather than focusing on genotype 10

Bottom Line

Double homozygous MTHFR mutations do not require specific management regarding sex hormones. The research associations are inconsistent, lack clinical validation, and most importantly, have no evidence-based interventions that improve reproductive or hormonal outcomes. Standard endocrine evaluation and treatment protocols should guide clinical decision-making, not MTHFR genotype 7, 8, 9.